BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue
Competitive Landscape Also Changing
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.
You may also be interested in...
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.